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Chronic hepatitis B virus (HBV) infection can cause hepatocellular carcinoma (HCC). Several hypotheses have been
proposed to explain the mechanisms of HBV tumorigenesis, including inflammation and liver regeneration
associated with cytotoxic immune injuries and transcriptional activators of mutant HBV gene products. The mutant
viral oncoprotein-driven tumorigenesis is prevailed at the advanced stage or anti-HBe-positive phase of chronic HBV
infection. Besides HBx, the pre-S2 (deletion) mutant protein represents a newly recognized oncoprotein that is
accumulated in the endoplasmic reticulum (ER) and manifests as type II ground glass hepatocytes (GGH). The retention
of pre-S2 mutant protein in ER can induce ER stress and initiate an ER stress-dependent VEGF/Akt/mTOR and NFκB/
COX-2 signal pathway. Additionally, the pre-S2 mutant large surface protein can induce an ER stress-independent pathway
to transactivate JAB-1/p27/RB/cyclin A,D pathway, leading to growth advantage of type II GGH. The pre-S2 mutant
protein-induced ER stress can also cause DNA damage, centrosome overduplication, and genomic instability. In 5-10%
of type II GGHs, there is co-expression of pre-S2 mutant protein and HBx antigen which exhibited enhanced oncogenic
effects in transgenic mice. The mTOR signal cascade is consistently activated throughout the course of pre-S2 mutant
transgenic livers and in human HCC tissues, leading to metabolic disorders and HCC tumorigenesis. Clinically, the
presence of pre-S2 deletion mutants in sera frequently develop resistance to nucleoside analogues anti-virals and
predict HCC development. The pre-S2 deletion mutants and type II GGHs therefore represent novel biomarkers of
HBV-related HCCs. A versatile DNA array chip has been developed to detect pre-S2 mutants in serum. Overall, the
presence of pre-S2 mutants in serum has implications for anti-viral treatment and can predict HCC development.
Targeting at pre-S2 mutant protein-induced, ER stress-dependent, mTOR signal cascade and metabolic disorders may
offer potential strategy for chemoprevention or therapy in high risk chronic HBV carriers.
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Hepatocellular carcinomaIntroduction
Hepatitis B virus ( HBV ) has been well established to cause
hepatocellular carcinoma ( HCCs ) [1]. Several hypotheses
have been proposed to explain the mechanism of HBV
tumorigenesis, including inflammation and liver regener-
ation associated with cytotoxic immune injuries, HBV DNA
insertional mutagenesis, and viral oncoproteins-driven
tumorigenesis [2-4]. Although HCC can occur at any stage
of chronic HBV infection, the majority of cases occur at the* Correspondence: suihjen@nhri.org.tw
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unless otherwise stated.advanced stage or anti-HBe-positive phase with the peak
incidence at sixth decade [4]. The development of HCC
related to the inflammation and liver regeneration is likely
due to the cytotoxic T cell immune injuries toward HBV
antigen-expressing hepatocytes which may result in bridg-
ing hepatic necrosis and fibrosis [3,5]. In the anti-HBe-
positive phase, however, the mutant viral oncoproteins may
play an important or driving role in HCC development.
In the early 1970s when the Australia antigen was found
to be associated with hepatitis B virus (HBV) infection,
Hadziyannis and Popper first recognized the surface antigen
in the “ground glass” hepatocytes (GGH) of HBV carriers
[6,7]. Under electron microscopy, GGHs are characterized
by an abundance of endoplasmic reticulum (ER), amongThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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believed that the overloaded ER makes the cytoplasms of
GGHs become “foggy” or “glassy”. After the introduction of
immunohistochemistry, a series of studies demonstrated
that different types of GGHs correlated to the expression
patterns of HBV surface/core antigens and the replicative
stages of chronic HBV infection [9,10]. Two types of GGHs
were later designated by us as type I and II GGHs [11].
Type I GGHs are usually scattered singly in the hepatic
lobules with the expression of “inclusion-like” pattern of
surface antigens (Figure 1A). This type of GGHs usually
occurs at the early stage or in patients with active diseases,
frequently co-expressed with a nuclear or cytoplasmic core
antigen [9,12,13]. Type II GGHs, however, express a unique
expression pattern of surface antigens at the cell margin
(Figure 1A). Most interestingly and importantly, type II
GGHs consistently cluster in nodules and usually occur at
the advanced stages or anti-HBe-positive phase [14], and
are frequently associated with cirrhosis or hepatocellularFigure 1 Two types of ground glass hepatocytes and the correspond
glass hepatocytes (GGH) and the expression patterns of hepatitis B surface antig
pattern of the surface antigen, while type II GGH consistently cluster in nodules
deletions over the pre-S regions in sera of HBV-related HCC patients. A complex
patients of chronic HBV carriers (B). Hematoxylin–Eosin stain, HE; Immunohistoccarcinoma (HCC). Conversion from type I GGH to type II
GGH could be demonstrated in the serial biopsies from
the same individual, frequently associated with hepatitis B
e antigen (HBeAg) seroconversion [14]. The consistent
clustering distribution of type II GGHs, especially in the
non-tumorous liver tissues of patients with HCC receiving
surgery, drives us to hypothesize that type II GGHs may
represent clonally-proliferated or preneoplastic lesions of
HCC [15]. The distinct marginal expression pattern of
surface antigens in type II GGHs suggests that there may
exist a unique form of mutant surface proteins which
exhibit growth advantage to promote the clustering distribu-
tion of hepatocytes.
The above-mentioned observation of the unique bio-
logic and pathologic features of type II GGHs drives us to
explore in details the underlying molecular and biologic
mechanism of type II GGHs and its potential significance
in HBV tumorigenesis. In the past decade, we clarified the
biologic and molecular significance of type II GGHs whiching deletions at pre-S regions of large surface protein. Ground
ens. Type I GGH are usually scattered singly and express an inclusion-like
and express a marginal pattern of the surface antigen (A). The profile of
combination of deletions at pre-S1 and pre-S2 regions may occur in
hemical stain, IHC.
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surface protein (pre-S2 mutant). The significance of pre-S2
mutant proteins in HCC development, the signal pathway
initiated by pre-S2 mutant proteins, and the transgenic mice
model of pre-S2 mutant tumorigenesis were studied in
detail. Importantly, we developed a DNA array chip to detect
pre-S2 mutant gene as the predictive marker of HCC in
chronic HBV carriers. Potential chemoprevention or therapy
targeting at mTOR signal cascade and metabolic pathway
was proposed in this review.
Review
Ground glass hepatocytes contain pre-S deletion mutant
proteins which accumulate in endoplasmic reticulum (ER)
and induce ER stress signals
By dissecting the cirrhotic nodules containing type II
GGHs, we are surprised to find that type II GGHs consist-
ently harbored pre-S2 mutants with in-frame deletions over
the pre-S2 regions (predominantly, nt. 2–55 or 4–57) with
or without point mutations at the start codon (ATG–ATA)
of the middle surface gene in the pre-S2 region. These
mutations lead to a decreased synthesis of middle and small
surface antigens and result in a defective secretion of the
mutant large surface antigens which then accumulate in
ER, leading to the GGH formation in chronic HBV infec-
tion [11,15]. It is also interesting to note that the deletion
site at the pre-S2 region coincides with the epitope of cyto-
toxic T-cell and B-cell neutralization responses and
suggests that the pre-S2 deletion mutants represent an im-
mune escape mutant [16,17], This hypothesis is supported
by the pathologic observation that the hepatic lobules,
which contain type II GGH, usually show no inflammatory
activities or lymphocyte infiltration [6,14,18]. Distinct from
type II GGHs, the singly distributed type I GGHs contain
entirely different pre-S mutants with variable deletions over
the pre-S1 regions. The deletion sites at the pre-S1 region
may interfere with the transcriptional activities of the pre-
S2/S promoter and affect the regulation of HBV replication
and synthesis of small surface antigens [19,20]. The pre-S1
containing large surface antigen (LHB) exhibits a dual
topology, and only half of the LHB translocate post-
translationally into the ER lumen [21,22]. The pre-S regions
that remain in cytoplasmic orientation can bind to the cyto-
solic heat shock protein Hsc70 [23] and presumably interact
with the core particle during virion assembly [24]. The cyto-
plasmic orientation of the pre-S region is required for the
transcriptional activator function of LHB and middle surface
protein in vitro [25,26]. The luminal orientation of the pre-S
domain, after virus maturation and secretion, is exposed on
the surface of the virion and is involved in virus attachment
and recognition [27,28]. Mutants with various types of in-
frame deletion in pre-S1 region were found to be replication
competent in vitro [17,20,29] and can be the predominant
strain in vivo [30-32]. In HCC patients, the pre-S mutantsare prevalent for up to 63%, including mutants with combi-
nations of deletions over the pre-S1 and pre-S2 regions
(Figure 1B) [33,34].
The accumulation of mutant or unfolded proteins
causes stress in ER that is sensed by the glucose-regulated
protein 78 (Grp78). Unfolded proteins will sequester
GRP78 and dissociate from three ER transmembrane
transducers leading to their activation [35]. The activation
of ER stress has been implicated in a variety of human
diseases including neurodegenerative disease, inflamma-
tion, and cancer [36]. It has been demonstrated that the
secretion of surface proteins was compromised by pre-S
deletions, especially pre-S2 mutants [11]. In addition,
ectopic expression of pre-S mutant proteins in Huh-7 cells
increased the levels of ER chaperones (Grp78 and 94) and
activated PERK and C-jun N-terminal kinase (JNK) [11].
These results indicate that both pre-S1 and pre-S2 mutant
surface proteins induce ER stress signals in hepatocytes.
In consistence with this assumption, elevated Grp78
expression was detected in both type I and type II GGHs
in the liver [11]. Northern and Western blot analyses
revealed that the pre-S1 mutant induced stronger levels of
ER chaperone (Grp78 and 94) response, calcium release,
cyclooxygenase-2 (COX-2) and inflammatory cytokines,
and oxidative stress intermediates, which tend to result in
apoptosis [11,37,38]. The pre-S2 mutants, albeit inducing
a weaker level of ER stress signal, exhibited higher levels
of mutation frequency and transforming capabilities in
primary hepatocyte cell line HH4 [39].
One remarkable biological phenomenon conferred by
pre-S1 and pre-S2 mutant proteins is the distinct subcellu-
lar localizations of these two proteins in the hepatocytes.
Accumulation of pre-S1 mutant proteins frequently
displayed an inclusion-like configuration in type I GGHs
(Figure 1). In contrast, peripheral or marginal distribution
of pre-S2 mutant proteins was evident in type II GGHs
[11,40]. It is plausible that marginal distribution of pre-S2
mutant proteins is a result of an active recruitment process
of pre-S2 mutant proteins, by other ER components,
towards the cell periphery. The triggering factor of this
recruitment and the patho-biological implication of this
process will shed light on the pathogenesis of GGHs as the
pre-neoplastic lesions for the development of HCC.
ER stress-dependent and-independent pathways induced
by pre-S2 mutants, leading to oxidative DNA damage,
genomic instability, and transforming capabilities in
transgenic mice model
The induction of ER stress has been shown to increase the
level of reactive oxygen species (ROS), NFκB activation and
cyclo-oxygenase-2 (COX-2) expression and thereby induces
oxidative DNA damages (Figure 2) [35-37]. Treatments
with antioxidants reduced ER stress and improved protein
folding [41]. As expected, the expression of pre-S mutant
Figure 2 Schematic depiction of the potential signals induced by pre-S mutants and the candidate targets for chemoprevention.
Both types of pre-S mutants can induce endoplasmic reticulum (ER) stress signals, which may lead to oxidative stress and DNA damage, leading
to genomic instability. The pre-S mutants may also activate two signal pathways to protect the hepatocytes from apoptosis, one involving nuclear
factor (NF)-κB to upregulate cyclooxygenase-2 (COX-2) and the other vascular endothelial growth factor to activate Akt/mammalian target of
Rapamy- cin (mTOR) signaling. Pre-S2 mutant can additionally induce an ER stress-independent c-Jun activation domain binding protein 1 (JAB1)/
p27/retinoblastoma (Rb)/adenovirus E2 promoter binding factor/cyclin A signal to initiate cell cycle progression. Combined effects of genomic
instability and cell proliferation will potentially result in carcinogenesis. Resveratrol and Silymarin are two nature products could be used to target
PPAR-α/γ and mTOR signal cascade for chemoprevention in high risk HBV carriers. Cdk2, cyclin-dependent kinase 2; HBV, hepatitis B virus; ROI,
reactive oxygen intermediate.
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by the increase in 8-hydroxyguanonine on the DNA lesion
and increased levels of 8-oxoguanine glycosylase 1 (ogg1)
and X-ray cross-complementation 1 (xrcc1) [38]. These
studies suggest the presence of genomic instability in GGHs
[42]. Notably, as a promising gene transactivator and an ER
stress inducer, pre-S2 mutant protein also promotes centro-
some instability through two independent mechanisms.
First, pre-S2 mutant protein could upregulate cyclin A and
sustained cyclin D1 and cyclin-dependent kinase-4 via gene
transactivation. This event subsequently promoted cell
cycle progression even in the presence of ER stress and
resulted in nodular proliferation in transgenic mice livers
[39]. Second, ER stress facilitates the release of calcium
from the ER and thereby activates calcium-dependent
calpain proteases. Notably, cyclin A is a substrate of calpain
and the proteolysis results in cytoplasmic redistribution of
cyclin A and thereby stimulates centrosome overduplica-
tion [43]. These studies demonstrate that pre-S2 mutant
protein is a direct driver of genomic instability through the
induction of DNA damages and centrosome abnormality.
The most important molecular mechanism initiated by
pre-S2 mutant is the VEGF/Akt/mTOR signal pathway
which is activated in Huh-7 cells and sequentially activated
at the early, middle, and advanced stages of transgenic livers
harboring pre-S2 deletion mutant (Figure 2) [44,45]. The
mTOR signaling is commonly activated in human HCCtissues and represents a candidate target for therapy. The
transforming ability of pre-S2 mutant proteins has been
investigated in an immortalized human hepatocyte line
HH4 [39]. In addition, transgenic mice carrying pre-S2
mutant developed HCC [40]. These studies further support
the role of pre-S2 mutants and GGHs in HBV hepatocarci-
nogenesis [14,46].
Aside from the ER stress-dependent signaling pathways,
a distinct ER stress-independent response has been found
specifically for pre-S2 deletion mutant protein and is
significant for their biologic and carcinogenic preferences
[11]. The pre-S2 mutant protein specifically interacts with
c-Jun activation domain binding protein 1 (JAB1), which
enhances activator protein-1 transcriptional activity and
cell proliferation [42]. Through its binding to JAB1, the pre-
S2 mutant protein induces JAB1 nuclear translocation,
which activates p27/retinoblastoma/Cdk2/cyclin A, D path-
ways and leads to cell cycle progression and centrosome
over-duplication [39,43]. These findings have provided clear
mechanisms for the growth advantage induced by the pre-
S2 mutant protein.
Two HBV viral proteins, the X protein (HBx) and pre-S2
deletion mutant protein, have been considered to have
either direct or indirect effects in HBV hepatocarcinogen-
esis [47]. Other than the molecular mechanisms of pre-S2
deletion mutants in hepatocarcinogenesis as mentioned
above, HBx also has been shown to mediate the activation
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cascade [48-52]. In our laboratory, we observed a strong
HBx expression in the cytosolic fraction of GGHs in 5 of 20
HBsAg-positive human livers. Interestingly, HBx was con-
sistently co-expressed with HBsAg, but not vice versa, in
GGHs. The expression of both oncoproteins, however, was
only rarely detected in HCC tissues [45]. Transgenic mice
harboring the HBx, pre-S2 mutant, and a double (HBx plus
pre-S2 mutant) construct have been established in our
laboratory. We observed that the transgenic livers harboring
double construct plasmids developed HCCs at an average of
15.1 months, earlier than that of HBx (16.9 months) or pre-
S2 mutant (24.5 months) alone. Interestingly, the oncogenic
signals of VEGF-A, p-Akt1/2/3, mitogen-activated protein
kinases (MAPK) signaling, and p-mTOR were sequentially
and differentially activated at different stages in the progres-
sion of tumorigenesis [45]. The combined expression of
HBx and pre-S2 mutant can exhibit enhanced oncogenic
effects in HBV tumorigenesis. The exact role of HBx and
pre-S2 mutant protein, either alone or in combination, in
human HCC development remains to be clarified.
Presence of pre-S2 mutants in serum predicts the resistance
of nucleoside analogues anti-virals and a higher risk of HCC
development
The emergence of pre-S deletion mutants occurs during
the natural course of HBV infection, possibly due to
selective pressure by the immune system [32,53]. The
frequencies of pre-S mutation increased successively in
different stage of chronic HBV infection. In a meta-
analysis study [54], the summarized results showed that
pre-S mutants were detected in around 10% of asymp-
tomatic HBsAg carriers, 20% of patients with chronic
hepatitis B, 35% of patients with liver cirrhosis and 50%
patients with HCC. The pre-S2 deletion mutants are
more frequently detected in anti-HBeAg-positive pa-
tients and in patients with HCC than in HBeAg-positive
patients [32,34,55]. The ratio of pre-S mutant clones
related to wild type in serum also accumulates, as it was
6.4% at high replicative phase, 13% at intermediate, and
37.5% at low or nonreplicative phases [34]. Therefore,
pre-S2 mutants represent a significant proportion of
virus in advanced stage patients [56,57].
Although anti-viral nucleoside analogues therapy has been
associated with a lower risk of HCC development or recur-
rence after liver resection in chronic HBV carriers [58], the
frequencies of pre-S mutants have been reported to be
increased after antiviral therapy by nucleos(t)ide analogues
which is closely associated with the drug resistance and
predict the high risk development of HCC [59,60]. Interest-
ingly, in the control group treated with alpha-interferon, the
pre-S2 mutants were significantly reduced or absent,
suggesting that alpha-interferon may degrade or inhibit the
synthesis of pre-S2 mutant proteins [59]. The presence ofpre-S mutants, especially pre-S2 mutant, has been found to
be significantly associated with the risk of HCC develop-
ment [59-64]. Pre-S deletion mutants detected in serum
has also been reported to increase the risk of post-operative
recurrence of HCC [65]. Of particular note, pre-S mutation
could occur early in age and significantly associated with
HCC in pediatric patients [66,67]. Pre-S2 deletion mutants
in sera can be detected in nearly half of children with HCC,
in contrast to none in children with chronic HBV infection
[66]. By using tissue samples, pre-S2 deletion mutants can
be detected in about 80% of pediatric HCC [67]. Overall,
the combined effects of cell cycle progression, genomic
instabilities, and survival advantage exhibited by pre-S2
mutant proteins strongly suggest that type II GGHs are
potential preneoplastic loci for HCC development and de
novo recurrence after surgical resection. In a cohort of 82
patients with HBV-related HCC who received curative
surgery [68], type II GGHs were found to be the inde-
pendent variables associated with late recurrence and the
overall survival. However, a prospective cohort study is
needed to test the specificity and sensitivity of pre-S2
deletion mutants and ground glass hepatocytes in the
predictive value of HCCs.
Development of DNA chip to detect pre-S2 mutants in
serum as the predictive hallmark of HCC
To efficiently detect pre-S deletion mutants in serum, we
have successfully developed the oligonucleotide Pre-S Gene
Chip to detect the pre-S deletion mutants in sera. The Pre-
S Gene Chip contains 42 DNA probes that target the pre-S
region of the LHBS gene, offering a highly sensitive and
specific method for pre-S deletion detection with short
turnaround time (≤3 days) [69]. Screening the pre-S dele-
tion mutants revealed interesting findings that the detection
rate of pre-S mutants were relatively low (7%) in the sera of
patients with acute exacerbation of chronic HBV infection
but gradually increased in later periods of chronic HBV
infection, as they were 37% in advanced stage of chronic
HBV carriers, and as high as 60% in HCC patients [69].
Combined detection of pre-S mutants and other markers of
HBV replication such as HBeAg and viral loads is believed
to offer a reliable predictive method for predicting HCC
risks in chronic HBV carriers.
Potential chemoprevention or therapy of HBV-related
HCCs targeting at ER stress-induced signal cascade and
metabolic disorders
Recently, metabolic disorders have been shown to be asso-
ciated with cancer development. In addition to its better-
known functions in promoting protein synthesis and
suppressing autophagy, mTOR is now emerging as a
key regulator of cellular metabolism and cancer [70]. By
analysis of metabolic gene expression profiles in transgenic
mice livers and in vitro culture system harboring pre-S2
Figure 3 Proposed model of HBV pre-S2 mutant-induced in metabolic disturbance and tumorigenesis. HBV pre-S2 mutant activated mTOR
through ER stress-dependent VEGF-A/Akt signal cascade. The activated mTOR induced glycolysis via YY1/c-Myc/Glut1 signaing and promoted de novo
lipogenesis through the activation of SREBP-1 and ACLY signals. The combined effects of aerobic glycolysis and de novo lipogenesis contributed to
growth advantages of hepatocytes and subsequent HCC development.
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significant role in the metabolic switch toward increased
glycolysis and lipid accumulation in HCC tissues (Figure 3).
We demonstrated that pre-S2 mutant could activate two
mTOR-induced metabolic pathways, one involving Yin
Yang 1 (YY1), c-myc and, glucose transporter 1 (GLUT1)
to upregulate aerobic glycolysis, and the other involving
sterol regulatory element-binding protein-1 (SREBP-1) and
acyl-CoA lyase (ACLY) to promote de novo lipid biosyn-
thesis (Teng C.F. et al., unpublished data). The activation of
mTOR-dependent metabolic signaling cascades was further
validated in human HBV-related HCC tissues. To protect
HBV carriers from developing HCC and preventing recur-
rence after HCC resection, it is important to develop
chemopreventive agents for the high risk patients targeting
at the specific signal pathway, with the combination of anti-
virals. Among the natural products, silymarin and resvera-
trol may represent potential candidate products because of
their popular and long-term usage in human communities
[71]. Silymarin, the active component-silibinin, has been
evaluated clinically in the treatment of hepatitis and liver
damage because of its anti-inflammation and anti-oxidant
effects [71,72]. Resveratrol has been verified to be effective
to prevent cancer development at various stages of carcino-
genesis including initiation, promotion, tumor invasion,
and metastatsis [73-75]. Importantly, resveratrol is also a
promising product for metabolic syndrome mediated
through mTOR inhibition and upregulation of PPARs and
PGC-1α [76,77]. The combination of silymarin and resvera-
trol could target on the major signal pathways induced by
pre-S2 mutants (Figure 2). Preliminary studies in our la-
boratory revealed a remarkable effect of this combinedproduct on reducing lipid metabolism and decreasing the
incidence of HCC development in transgenic mice harbor-
ing HBx and pre-S2 mutant [78]. Further studies or clinical
trials are needed to validate the effect of the natural prod-
ucts, with or without the combination of antivirals in che-
moprevention or therapy of HBV-related HCCs.
Conclusion
In this review, we provide a comprehensive overview to
provide evidence on the emerging role of HBV pre-S2
deletion mutant protein in HBV tumorigenesis. The
HBV pre-S2 deletion mutant proteins are retained in the
ER and induce ER stress response. Series of ER stress-
dependent and -independent growth signals are then ac-
tivated. Among the diverse pathways, mTOR-mediated
signal cascade represent a major mechanism for the dis-
turbed metabolism, genomic instability, and growth
advantage, which drive the type II GGHs toward the
pre-neoplastic and neoplastic lesions. To identify the
patients at high risk for HCC development represents
the major task in combating chronic HBV infection in
the coming decades. The development of a DNA chip
for detecting pre-S2 deletion mutant will meet this
demand. Chemopreventive or therapeutic agents can
then be provided to these high risk HBV carriers to
prevent from HCC development.
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